Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany

By Greiner W.   Lehmann K.   Earnshaw S.   Bug C.   Sabatowski R.  

The European Journal of Health Economics, Vol. 7, Iss. 4, 2006-12 ,pp. : 290-296

Springer Publishing Company

Access to resources Recommend Favorite

Methods for determining cost-benefit ratios for pharmaceuticals in Germany

By Graf v. d. Schulenburg J.-   Vauth Christoph   Mittendorf Thomas   Greiner Wolfgang  

The European Journal of Health Economics, Vol. 8, Iss. 1, 2007-09 ,pp. : 5-31

Springer Publishing Company

Access to resources Recommend Favorite

HEALTH TECHNOLOGY ASSESSMENT IN EVALUATION OF PHARMACEUTICALS IN THE CZECH REPUBLIC

By  

International Journal of Technology Assessment in Health Care, Vol. 33, Iss. 3, 2017-04 ,pp. : 339-344

Cambridge University Press

Access to resources Recommend Favorite

The burden of varicella in Germany: Potential risks and economic impact

By Banz Kurt   Wagenpfeil Stefan   Neiss Albrecht   Hammerschmidt Thomas   Wutzler Peter  

The European Journal of Health Economics, Vol. 5, Iss. 1, 2004-02 ,pp. : 46-53

Springer Publishing Company

Access to resources Recommend Favorite

Priority setting for pharmaceuticals: The use of health economic evidence by reimbursement and clinical guidance committees

By Anell Anders  

The European Journal of Health Economics, Vol. 5, Iss. 1, 2004-02 ,pp. : 28-35

Springer Publishing Company

Access to resources Recommend Favorite